The 2026 Peptide Tier List

Every few months a new "peptide tier list" circulates on fitness forums — typically authored by people with strong opinions and thin evidence. This one reverses the priority: quality of evidence first, effect size second, internet buzz zero.

Tier S — Clinically validated, large effect

Semaglutide, Tirzepatide. These are the only two peptides in this tier. Phase-3 trials across tens of thousands of patients, FDA approval for both diabetes and obesity, and — in semaglutide's case — documented reductions in major cardiovascular events (SELECT, 2023). Effect size is dominant: 15–22% weight reduction over 68+ weeks. Nothing else is close.

Tier A — Evidence-backed, specific use cases

Tesamorelin. FDA-approved. Consistent 15–20% visceral adipose reduction. Narrower indication than GLP-1s but the strongest evidence for any GHS-class peptide.

GHK-Cu (topical). Decades of cosmetic dermatology research, gene-expression data on ~4,000 human genes, reproducible skin-remodeling effects. Modest effect size for wrinkles, but well-supported.

Tier B — Promising preclinical, limited human data

BPC-157, TB-500. Strong rodent signal for tissue healing. Human evidence is preliminary. Widespread off-label use does not substitute for trial data. FDA's 2023 section 503A listing is a regulatory reality check.

CJC-1295 + Ipamorelin. The best-characterized GHS stack, with documented GH/IGF-1 elevation in small studies. Effect sizes for body composition are modest in trained populations.

Tier C — Interesting science, very early

MOTS-c, Epitalon, Sermorelin. Each has a valid biological rationale and some data, but no robust controlled human trials demonstrating meaningful clinical endpoints. Use is heavily influenced by practitioner tradition rather than evidence.

Tier D — Overhyped, under-evidenced

AOD-9604. The GH 176-191 fragment. Extensive marketing, weak human efficacy data at available doses. Did not meet phase-2b weight-loss endpoints.

PT-141 (bremelanotide for sexual dysfunction). An exception — FDA-approved, works, but falls outside the fitness-peptide conversation it's often bundled with.

The meta-point

Peptide hype moves faster than peptide evidence. The gap between "this molecule works in mice and internet forums say it's transformative" and "this molecule works in a controlled human trial" is enormous. Use that gap to calibrate expectations.